文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

心脏ATTR淀粉样变性疾病进展分层

Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis.
PubMed 文献 · J Am Coll Cardiol · 2024-03-01

本研究在2275例心脏ATTR淀粉样变性患者中评估NT-proBNP进展和门诊利尿剂强化作为疾病进展标志物的预后价值。NT-proBNP进展和门诊利尿剂强化均与死亡率增加独立相关,两者并存时风险更高,提示联合这两个变量可简单检测疾病进展。

要点

  • NT-proBNP进展(升高>700 ng/L且>30%)与死亡风险增加相关。
  • 门诊利尿剂强化与死亡风险增加相关。
  • 两者并存时死亡风险更高,可联合用于疾病进展分层。

核心结论

  • NT-proBNP进展和门诊利尿剂强化在心脏ATTR淀粉样变性患者中常见,且与死亡风险增加 consistently 相关。
  • 联合这两个变量可形成简单、普遍适用的模型来检测疾病进展。

研究设计与样本

  • 研究纳入来自7个专科中心的2275例心脏ATTR淀粉样变性患者,其中National Amyloidosis Centre队列1598例用于变量开发,外部验证队列677例。
  • 采用里程碑生存分析,评估诊断至1年访视期间NT-proBNP进展和门诊利尿剂强化与后续死亡率的关系。

主要发现

  • NAC队列中551例(34.5%)和外部验证队列中204例(30.1%)患者出现NT-proBNP进展,与死亡率相关(NAC队列:HR 1.82,95%CI 1.57-2.10,P<0.001;验证队列:HR 1.75,95%CI 1.32-2.33,P<0.001)。
  • 1年时,NAC队列451例(28.2%)和外部验证队列301例(44.5%)患者出现门诊利尿剂强化,与死亡率相关(NAC队列:HR 1.88,95%CI 1.62-2.18,P<0.001;验证队列:HR 2.05,95%CI 1.53-2.74,P<0.001)。
  • 与NT-proBNP稳定且利尿剂剂量稳定的患者相比,出现NT-proBNP进展或门诊利尿剂强化的患者死亡风险更高(NAC队列:HR 1.93,95%CI 1.65-2.27,P<0.001;验证队列:HR 1.94,95%CI 1.36-2.77,P<0.001)。
  • 同时出现NT-proBNP进展和门诊利尿剂强化的患者死亡风险最高(NAC队列:HR 2.98,95%CI 2.42-3.67,P<0.001;验证队列:HR 3.23,95%CI 2.17-4.79,P<0.001)。

关键数值与推荐

  • NT-proBNP进展定义为NT-proBNP升高>700 ng/L且>30%。
  • 门诊利尿剂强化定义为需要增加利尿剂治疗。

临床怎么用

  • 在心脏ATTR淀粉样变性患者随访中,应监测NT-proBNP水平和利尿剂需求变化。
  • NT-proBNP进展和门诊利尿剂强化可联合用于识别疾病进展高风险患者,指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. OBJECTIVES: The goal of this study was to assess the prognostic importance of an increase in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and outpatient diuretic intensification (ODI) as markers of disease progression in a large cohort of patients with ATTR-CA. METHODS: We evaluated landmark survival analysis based on worsening of NT-proBNP and requirement for ODI between time of diagnosis and a 1-year visit, and subsequent mortality in 2,275 patients with ATTR-CA from 7 specialist centers. The variables were developed in the National Amyloidosis Centre (NAC) cohort (n = 1,598) and validated in the external cohort from the remaining centers (n = 677). RESULTS: Between baseline and 1-year visits, 551 (34.5%) NAC patients and 204 (30.1%) patients in the external validation cohort experienced NT-proBNP progression (NT-proBNP increase >700 ng/L and >30%), which was associated with mortality (NAC cohort: HR: 1.82; 95% CI: 1.57-2.10; P < 0.001; validation cohort: HR: 1.75; 95% CI: 1.32-2.33; P < 0.001). At 1 year, 451 (28.2%) NAC patients and 301 (44.5%) patients in the external validation cohort experienced ODI, which was associated with mortality (NAC cohort: HR: 1.88; 95% CI: 1.62-2.18; P < 0.001; validation cohort: HR: 2.05; 95% CI: 1.53-2.74; P < 0.001). When compared with patients with a stable NT-proBNP and stable diuretic dose, a higher risk of mortality was observed in those experiencing either NT-proBNP progression or ODI (NAC cohort: HR: 1.93; 95% CI: 1.65-2.27; P < 0.001; validation cohort: HR: 1.94; 95% CI: 1.36-2.77; P < 0.001), and those experiencing both NT-proBNP progression and ODI (NAC cohort: HR: 2.98; 95% CI: 2.42-3.67; P < 0.001; validation cohort: HR: 3.23; 95% CI: 2.17-4.79; P < 0.001). CONCLUSIONS: NT-proBNP progression and ODI are frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in ATTR-CA.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ioannou A, Cappelli F, Emdin M, et al. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis. J Am Coll Cardiol. 2024. PMID: 38530684. doi:10.1016/j.jacc.2023.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。